Tissium announced today that it raised approximately $68 million (€60 million) in a financing round.
The financing for the Paris-based company, which has its U.S. base in Cambridge, Massachusetts, includes $34 million (€30 million) from a Series D2 financing, alongside $34 million (€30 million) from a European Investment Bank (EIB) financing facility.
According to Tissium, the financing comes amid a “transformational stage” for the company. It received FDA authorization for its Coaptium Connect with Tissium Light, a first-of-its-kind atraumatic sutureless solution for peripheral nerve repair, last year. The company began its commercial entry into the U.S. and said it continues to make progress across a pipeline of products addressing unmet needs in atraumatic nerve repair, atraumatic hernia repair and cardiovascular applications.
Read full article: https://www.massdevice.com/tissium-closes-68m-financing-for-tissue-reconstruction-polymers/
